EGFR and non-small cell lung carcinoma: In one study, whole-exome sequencing (WES) and RNA sequencing were performed in 36 BM of various origins, including 18 NSCLC-BM samples, identifying potentially actionable alterations in several genes including AKT1, CDK6, EGFR, MEK1, and MET. 8In a large-scale pan-cancer study, 2583 metastases from 20 different tumor types were profiled by whole-genome sequencing (WGS).9